Where to Buy Jardiance: Vendor Comparison & Research Info

Jardiance (Empagliflozin) is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor studied in metabolic, renal, and cardiovascular research. It provides a useful research model for investigating renal glucose handling, urinary glucose excretion, fluid balance, energy metabolism, and pathways connecting glucose regulation with cardiovascular and kidney function.

Overview

Empagliflozin acts primarily on SGLT2, a transporter responsible for the majority of glucose reabsorption in the proximal renal tubule. Inhibition of this transporter reduces renal glucose reabsorption and increases urinary glucose excretion.

Beyond glucose transport, empagliflozin is extensively investigated for its effects on renal physiology, hemodynamics, metabolic signaling, and cardiovascular biology.

Molecular Characteristics

• Active Ingredient: Empagliflozin

• Pharmacological Class: SGLT2 inhibitor

• Molecular Formula: C₂₃H₂₇ClO₇

• Molecular Weight: Approximately 450.9 g/mol

• CAS Number: 864070-44-0

• Research Category: Metabolic, renal, and cardiovascular research

Research Applications

Empagliflozin can be investigated across several scientific fields:

• SGLT2 transporter biology

• Renal glucose reabsorption

• Glucose homeostasis

• Renal sodium handling

• Cardiovascular physiology

• Kidney-function research

• Energy metabolism

• Fluid and electrolyte regulation

• Metabolic signaling

• Pharmacokinetic and pharmacodynamic research

Mechanism of Action

Empagliflozin selectively inhibits SGLT2 in the proximal renal tubule. Under normal physiological conditions, SGLT2 transports filtered glucose and sodium from the renal tubular lumen back into circulation.

Blocking this transporter decreases glucose reabsorption and increases urinary glucose elimination. SGLT2 inhibition also alters sodium handling, which can influence renal tubular signaling and downstream hemodynamic responses.

Key Mechanistic Features

Renal Glucose Transport:
Empagliflozin provides a model for studying the molecular mechanisms controlling glucose reabsorption in the kidney.

Glucosuria:
SGLT2 inhibition increases urinary glucose excretion, allowing researchers to examine glucose disposal independently of insulin-mediated pathways.

Sodium Handling:
Changes in sodium reabsorption can be investigated in relation to renal tubular function and fluid regulation.

Metabolic Effects:
Research can examine how altered renal glucose handling affects whole-body energy balance and metabolic signaling.

Primary Research Areas

1. Glucose Metabolism

Empagliflozin is widely studied for understanding how renal glucose transport contributes to systemic glucose homeostasis.

2. Renal Physiology

Experimental models can investigate proximal tubular transport, sodium-glucose cotransport, urinary glucose elimination, and renal hemodynamics.

3. Cardiovascular Research

Researchers study interactions between SGLT2 inhibition, fluid balance, vascular function, cardiac metabolism, and cardiovascular physiology.

4. Kidney Research

Empagliflozin provides a model for examining metabolic and hemodynamic mechanisms associated with renal function and kidney protection.

5. Energy Metabolism

Research may explore how increased urinary glucose loss influences substrate utilization, metabolic flexibility, and cellular energy pathways.

Pharmacological Research

Empagliflozin may be evaluated in studies involving:

• Absorption and bioavailability

• Plasma exposure

• Renal elimination

• Metabolite formation

• Transporter selectivity

• Drug–drug interactions

• Pharmacodynamic glucose responses

• Renal and cardiovascular biomarkers

Analytical Testing

Empagliflozin formulations may undergo analytical characterization using:

• High-Performance Liquid Chromatography (HPLC)

• Liquid Chromatography–Mass Spectrometry (LC-MS)

• Identity testing

• Assay and purity determination

• Dissolution testing

• Stability analysis

• Content uniformity assessment

These procedures help verify chemical identity, formulation consistency, and stability for controlled research applications.

Storage & Handling

Jardiance should be stored and handled according to applicable product documentation and pharmaceutical or laboratory requirements. Researchers should consult formulation-specific specifications and the relevant Certificate of Analysis before experimental use.

Safety & Research Disclaimer

Empagliflozin is a pharmacologically active compound that alters renal glucose and sodium handling. Research should be conducted by qualified personnel using appropriate laboratory, institutional, and regulatory procedures.

Jardiance (Empagliflozin) is intended for legitimate scientific and research applications and should not be used for self-treatment or unsupervised therapeutic use.